Eli Lilly (LLY) Stock: Company Loads Up $1.5B of Weight-Loss Pills to Battle Wegovy

TLDR Eli Lilly stockpiled $1.5 billion of Orforglipron weight-loss pill before expected April 2026 FDA approval Strategy aims to prevent supply shortages that hurt Zepbound and Mounjaro launches in 2022 Novo Nordisk’s oral Wegovy reached 50,000 prescriptions by January after December 2025 approval Orforglipron could hit $13 billion in annual sales by 2031 according to [...]

The post Eli Lilly (LLY) Stock: Company Loads Up $1.5B of Weight-Loss Pills to Battle Wegovy appeared first on Blockonomi.